Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.

PloS one

Volumn 7, Issue 4, 2012, Pages

  Lu, Charles ^a   Stewart, David J ^b   Lee, J Jack ^b   Ji, Lin ^b   Ramesh, Rajagopal ^b   Jayachandran, Gitanjali ^b   Nunez, Maria I ^b   Wistuba, Ignacio I ^b   Erasmus, Jeremy J ^b   Hicks, Marshall E ^b   Grimm, Elizabeth A ^b   Reuben, James M ^b   Baladandayuthapani, Veerabhadran ^b   Templeton, Nancy S ^b   McMannis, John D ^b   Roth, Jack A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYLOXY 3 (TRIMETHYLAMMONIUM)PROPANE; 1,2-DIOLEOYLOXY-3-(TRIMETHYLAMMONIUM)PROPANE; MONOUNSATURATED FATTY ACID; NANOPARTICLE; QUATERNARY AMMONIUM DERIVATIVE; TUMOR SUPPRESSOR PROTEIN; TUSC2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; LUNG TUMOR; MAXIMUM TOLERATED DOSE; METABOLISM; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PLASMID; POSITRON EMISSION TOMOGRAPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; GENE EXPRESSION PROFILING; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; NANOPARTICLES; PLASMIDS; POSITRON-EMISSION TOMOGRAPHY; QUATERNARY AMMONIUM COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84865850008     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034833     Document Type: Article

References (0)